Phase Ib/II Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of ‘Switch Maintenance’ Combination Immunotherapy Using AB154, AB122, and Sotigalimab in Patients with Metastatic Pancreatic Cancer

Protocol # :
Pancreatic Cancer
Adenocarcinoma of the Pancreas
Squamous Cell Carcinoma of Pancreas
Adenosquamous Carcinoma of the Pancreas
Disease Sites
Principal Investigator
Cleary, James, M

Trial Description

This study is being done to test the safety and effectiveness of combining domvanalimab
(AB154), zimberelimab (AB122), and APX005M with pancreatic cancer that has spread to other
parts of body.

This research study involves immunotherapy. Immunotherapy triggers the body's immune system
to fight cancer cells.

The names of the study drugs involved in this study are:

- Domvanalimab (also known as AB154)

- Zimberelimab (also known as AB122)

- APX005M

Eligibility Requirements

Inclusion Criteria:

- Participants must have histologically confirmed pancreatic cancer (adenocarcinoma,
squamous, or adenosquamous histologies) that is metastatic and for which standard
curative or palliative measures do not exist or are no longer effective. Locally
advanced patients are not eligible.

- Participants must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray
or as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam.

- Participants must have received 8-12 cycles (4-6 months) of first-line FOLFIRINOX or
modified FOLFIRINOX with stable disease or better.

- Age ≥18 years. Because no dosing or adverse event data are currently available on the
use of domvanalimab + zimberelimab + APX005M in participants <18 years of age,
children are excluded from this study.

- ECOG performance status ≤1

- Participants must have adequate organ and marrow function as defined below:

- leukocytes ≥3,000/mcL

- absolute neutrophil count ≥1,500/mcL

- platelets ≥100,000/mcL

- total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN), except in
patients with documented Gilbert's syndrome, who must have a total bilirubin ≤ 3

- AST(SGOT)/ALT(SGPT) ≤ 2.5 x institution's upper limit of normal (ULN) for
patients with no concurrent liver metastases, OR ≤ 5.0 x institution's ULN for
patients with concurrent liver metastases creatinine OR glomerular filtration
rate (GFR) creatinine ≤ 2 x ULN OR GFR measured by calculated creatinine
clearance (CrCl) > 45 mL/min. CrCl can be calculated using the Cockroft-Gault

- Hemoglobin (Hgb) >9.0 g/dL

- Participants with treated brain metastases are eligible if follow-up brain imaging
after central nervous system (CNS)-directed therapy shows no evidence of progression.
If a participant has brain or meningeal metastases, the participant must meet the
following criteria:

- Have no evidence of progression by neurologic symptoms or sign for at least 4
weeks prior to the first dose.

- Metastatic brain lesions do not require immediate intervention.

- Carcinomatous meningitis is excluded regardless of clinical stability.

- Participants with known history or current symptoms of cardiac disease, or history of
treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
function using the New York Heart Association Functional Classification. To be
eligible for this trial, participants should be class 2B or better.

- Participants must be willing to undergo a pre-treatment fresh tumor biopsy.

- Participants must be willing to undergo an on-treatment tumor biopsy (if medically

- Participants must have archival tissue available for analysis, which will be used for
correlative studies if a pretreatment biopsy reveals necrotic tissue.

- The effects of domvanalimab, zimberelimab, and APX005M on the developing human
fetus are unknown. For this reason, women of child-bearing potential and men must
agree to use adequate contraception (See Section 5.6) prior to study entry and
for the duration of study participation. Should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study,
she should inform her treating physician immediately. Men treated or enrolled on
this protocol must also agree to use adequate contraception prior to the study,
for the duration of study participation, and 4 months after completion of
domvanalimab, zimberelimab, or APX005M administration.

- Women of childbearing potential (WOCBP), defined as not surgically sterilized and
between menarche and 1-year post menopause, must have a negative serum pregnancy
test within 7 days prior to the first dose of investigational therapies and a
negative urine (or serum) pregnancy test within 3 days prior to the first dose of
investigational therapies.

- WOCBP must agree to use highly effective methods of contraception from the time
of consent, through the duration of study treatment, and 5 months after the last
dose of investigational therapies.

- Male participants with WOCBP sexual partners must agree to use highly effective
methods of contraception, and to refrain from donating sperm from the time of
consent through the duration of study treatment and 7 months after the last dose
of investigational therapies. Contraceptive requirements may be extended
depending on local regulatory requirements.

- Female participants must not be breast feeding and must not breast-feed a baby
while on treatment and for up to 7 months after the last dose of investigational

- Ability to understand and the willingness to sign a written informed consent document.

- Willing and able to comply with the requirements and restrictions in this protocol.

- Eligibility Criteria for Stage 2 (Crossover Stage)

- Patients must meet all of the criteria used for Stage 1.

- Patients allocated to the control arm (Arm B) during Stage 1 have the ability to
initiate Stage 2 treatment within 4 weeks after experiencing disease progression
per RECIST v1.1 while receiving control treatment

- Availability of a tumor specimen from on-treatment biopsy during Expansion Phase. If
this is not available, willingness to undergo biopsy prior to initiation of Crossover

- Exclusion Criteria (for both Stage 1 and Stage 2)

- Patients who have evidence of disease progression on FOLFIRINOX.

- Participants who have had cytotoxic chemotherapy, radiotherapy, within 2 weeks prior
to the first dose of study medication or those who have not recovered to ≤ CTCAE Grade
1 or baseline from adverse events due to agents administered more than 2 weeks
earlier. Exceptions include alopecia of any grade and Grade ≤ 2 peripheral neuropathy.

- Participants who have received any other investigational agents for pancreatic cancer.

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies, or allergic reactions attributed to compounds of
similar chemical or biologic composition to domvanalimab, zimberelimab, APX005M, or
other agents used in study.

- Prior treatment with any of the protocol-specified study treatments, with the
exception of chemotherapy.

- Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies
(including anti-CTLA-4, anti-PD-1, anti-PD-L1, anti-TIGIT, and CD40 agonist
therapeutic antibodies)

- Patients with endocrine or acinar pancreatic carcinoma are not eligible for the study.

- Known dihydropyrimidine dehydrogenase deficiency.

- Known germline BRCA1 or BRCA2 mutation(s).

- Participants who have undergone major surgery 28 days prior to initiating protocol
therapy. Participants must have sufficiently recovered from adverse events caused by
the procedure as judged by the treating investigator. Placement of central venous
access catheter (e.g., port or similar) is not considered a major surgical procedure.

- Participants must not have a history of human immunodeficiency virus (HIV), hepatitis
B (HBV), or hepatitis C (HCV), except for the following:

- Participants with anti-HepB core antibody but with undetectable HepB virus
deoxyribonucleic acid (DNA) and negative for HepB surface antigen

- Participants with resolved or treated hepatitis C virus (HCV) (i.e., HCV antibody
positive but undetectable HCV RNA)

- Participants must not have a history of primary immunodeficiency.

- Active autoimmune disease, history of autoimmune disease, or concurrent administration
of immune suppressive medications. Participants must not have a known or suspected
history of an autoimmune disorder within 3 years of the first dose of investigational
agent, including but not limited to: systemic lupus erythematosus, scleroderma,
inflammatory bowel disease, celiac disease, Wegner syndrome, Hashimoto syndrome,
sarcoidosis, or autoimmune hepatitis. Exceptions include participants with Type 1
diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders
such as alopecia or vitiligo, not requiring systemic therapy, resolved childhood
asthma/atopy, or conditions not expected to recur in the absence of an external
trigger are eligible. Patients with a history of Hashimoto syndrome within 3 years of
the first dose of investigational agent, which resolved to hypothyroidism alone.

- Prior allogeneic bone marrow transplantation or solid organ transplantation.

- Participants must not receive concurrent or prior use of an immunosuppressive agent
within 14 days prior to the first dose of investigational agent. Exceptions include:

- Systemic steroids at physiologic doses (equivalent to dose of ≤ 10 mg oral
prednisone) are permitted.

- Intranasal, inhaled, topical, intra-articular, and ocular corticosteroids with
minimal systemic absorption are permitted.

- Patients with a condition with anticipated use of systemic steroids above the
equivalent of 10 mg prednisone are excluded.

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
chest CT scan.

- Patients must not have received a live attenuated vaccine within 28 days before the
first dose of investigational agent, and patients, if enrolled, should not receive
live vaccines during the study or for 180 days after the last dose of investigational
agent. Prior COVID-19 infection and/or COVID-19 vaccination is permitted.

- Known hereditary or acquired coagulopathy (e.g., hemophilia, von Willebrand disease,
cancer-associated diffuse intravascular coagulation)

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection (viral, bacterial, or fungal infections requiring parenteral treatment
within 14 days of the initiation of investigational therapy), clinically significant
cardiovascular disease, unstable angina pectoris, cardiac arrhythmia, uncontrolled
major seizure disorder, unstable spinal cord compression, superior vena cava syndrome,
or psychiatric illness/social situations that would limit compliance with study

- Participants with a history of a clinically relevant second primary malignancy within
the past 2 years. Exceptions include: resected basal and squamous cell carcinomas of
the skin and completely resected carcinoma in situ of any type.